Skip to main navigation

Skip to Content

News
Contact Us
Investors
- Overview
- Events and Presentations
- SEC Filings
- Stock Information
- Corporate Governance
- Investor FAQs
- Email Alerts

Home
About
- About Cullinan
- Leadership
- Partnerships
Research
- R&D
- Programs
- Pipeline
For Patients
- Patient Programs
- Clinical Trials
Working at Cullinan
- Our People
- Careers

News Releases

Year

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

June 1, 2024

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 24, 2024

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 23, 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

April 29, 2024

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

April 24, 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 16, 2024

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

April 16, 2024

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 14, 2024

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

March 1, 2024

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 21

Connect With Us

Follow Us

Site - Social

Site - Footer

Connect With Us
Terms of Use
Privacy Notice
Cookie Notice
Accessibility Policy

© COPYRIGHT 2024 Cullinan Therapeutics, Inc. | ALL RIGHTS RESERVED